Nessima Yelles

Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes

E. Vicaut, M. Giroud, P. Touboul, 2019, European stroke journal.

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke

E. Vicaut, D. Leys, A. Leger, 2020, Stroke.

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

E. Vicaut, M. Dougados, M. Humbert, 2021, The Lancet Respiratory Medicine.

A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.

E. Vicaut, D. Leys, Y. Samson, 2019, The New England journal of medicine.

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

E. Vicaut, M. Dougados, M. Humbert, 2021, The Lancet Rheumatology.